GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » Gross Margin %

Merus Labs International (Merus Labs International) Gross Margin % : 62.80% (As of Mar. 2017)


View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Merus Labs International's Gross Profit for the three months ended in Mar. 2017 was $10.62 Mil. Merus Labs International's Revenue for the three months ended in Mar. 2017 was $16.92 Mil. Therefore, Merus Labs International's Gross Margin % for the quarter that ended in Mar. 2017 was 62.80%.


The historical rank and industry rank for Merus Labs International's Gross Margin % or its related term are showing as below:


MSLI's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 46.765
* Ranked among companies with meaningful Gross Margin % only.

Merus Labs International had a gross margin of 62.80% for the quarter that ended in Mar. 2017 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Merus Labs International was 0.00% per year.


Merus Labs International Gross Margin % Historical Data

The historical data trend for Merus Labs International's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International Gross Margin % Chart

Merus Labs International Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.64 91.37 82.82 84.61 67.13

Merus Labs International Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.15 65.62 63.66 68.85 62.80

Competitive Comparison of Merus Labs International's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus Labs International's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Merus Labs International's Gross Margin % falls into.



Merus Labs International Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Merus Labs International's Gross Margin for the fiscal year that ended in Sep. 2016 is calculated as

Gross Margin % (A: Sep. 2016 )=Gross Profit (A: Sep. 2016 ) / Revenue (A: Sep. 2016 )
=46.6 / 69.481
=(Revenue - Cost of Goods Sold) / Revenue
=(69.481 - 22.839) / 69.481
=67.13 %

Merus Labs International's Gross Margin for the quarter that ended in Mar. 2017 is calculated as


Gross Margin % (Q: Mar. 2017 )=Gross Profit (Q: Mar. 2017 ) / Revenue (Q: Mar. 2017 )
=10.6 / 16.918
=(Revenue - Cost of Goods Sold) / Revenue
=(16.918 - 6.294) / 16.918
=62.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Merus Labs International  (NAS:MSLI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Merus Labs International had a gross margin of 62.80% for the quarter that ended in Mar. 2017 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Merus Labs International Gross Margin % Related Terms

Thank you for viewing the detailed overview of Merus Labs International's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus Labs International (Merus Labs International) Business Description

Traded in Other Exchanges
N/A
Address
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines